Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
BDH INDUS. ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BDH INDUS. Mar-23 |
ADCOCK INGRAM Jun-14 |
BDH INDUS./ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 211 | 325 | - | |
Low | Rs | 93 | 234 | - | |
Sales per share (Unadj.) | Rs | 129.3 | 96.6 | - | |
Earnings per share (Unadj.) | Rs | 14.2 | -24.3 | - | |
Cash flow per share (Unadj.) | Rs | 15.2 | -20.2 | - | |
Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
Avg Dividend yield | % | 2.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 95.0 | 75.8 | - | |
Shares outstanding (eoy) | m | 5.76 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.2 | 2.9 | 40.6% | |
Avg P/E ratio | x | 10.7 | -11.5 | -92.8% | |
P/CF ratio (eoy) | x | 10.0 | -13.9 | -71.9% | |
Price / Book Value ratio | x | 1.6 | 3.7 | 43.4% | |
Dividend payout | % | 28.1 | 0 | - | |
Avg Mkt Cap | Rs m | 874 | 47,183 | 1.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 70 | 2,961 | 2.3% | |
Avg. sales/employee | Rs Th | 0 | 3,798.6 | - | |
Avg. wages/employee | Rs Th | 0 | 689.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -957.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 745 | 16,307 | 4.6% | |
Other income | Rs m | 8 | 114 | 7.4% | |
Total revenues | Rs m | 753 | 16,421 | 4.6% | |
Gross profit | Rs m | 110 | -2,826 | -3.9% | |
Depreciation | Rs m | 6 | 704 | 0.8% | |
Interest | Rs m | 2 | 442 | 0.4% | |
Profit before tax | Rs m | 111 | -3,857 | -2.9% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 29 | 241 | 11.9% | |
Profit after tax | Rs m | 82 | -4,109 | -2.0% | |
Gross profit margin | % | 14.7 | -17.3 | -84.9% | |
Effective tax rate | % | 25.9 | -6.2 | -414.0% | |
Net profit margin | % | 11.0 | -25.2 | -43.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 605 | 11,944 | 5.1% | |
Current liabilities | Rs m | 246 | 6,720 | 3.7% | |
Net working cap to sales | % | 48.2 | 32.0 | 150.4% | |
Current ratio | x | 2.5 | 1.8 | 138.3% | |
Inventory Days | Days | 3 | 111 | 2.3% | |
Debtors Days | Days | 816 | 124 | 658.2% | |
Net fixed assets | Rs m | 195 | 6,962 | 2.8% | |
Share capital | Rs m | 58 | 76 | 76.0% | |
Net worth | Rs m | 547 | 12,799 | 4.3% | |
Long term debt | Rs m | 0 | 4,498 | 0.0% | |
Total assets | Rs m | 800 | 24,179 | 3.3% | |
Interest coverage | x | 71.1 | -7.7 | -918.9% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.7 | 138.0% | |
Return on assets | % | 10.4 | -15.2 | -68.9% | |
Return on equity | % | 15.0 | -32.1 | -46.7% | |
Return on capital | % | 20.5 | -19.8 | -103.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 63 | 1,392 | 4.5% | |
From Investments | Rs m | 5 | -427 | -1.1% | |
From Financial Activity | Rs m | 4 | 4,082 | 0.1% | |
Net Cashflow | Rs m | 71 | 5,047 | 1.4% |
Compare BDH INDUS. With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare BDH INDUS. With: AARTI DRUGS SMRUTHI ORGANICS PARMAX PHARMA UNICK FIX-A-FORM AND PRINTERS AUROBINDO PHARMA
After opening the day on positive note, Indian share markets reversed the trend as the session progressed and ended lower.